An Information Portal to 111558 Biological Macromolecular Structures

P1B is found in 2 entries
  •   Chemical Component Summary   Hide
    Name (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione
    Identifiers (5R)-5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
    Formula C19 H20 N2 O3 S
    Molecular Weight 356.44 g/mol
    Type non-polymer
    Isomeric SMILES
  •   Drug Info: DrugBank Hide
    DrugBank ID DB01132   (Different stereochemistry)
    Name Pioglitazone
    • approved
    • investigational
    Description Pioglitazone is used for the treatment of diabetes mellitus type 2. Pioglitazone selectively stimulates nuclear receptor peroxisone proliferator-activated receptor gamma (PPAR-gamma). It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the lipidic, muscular tissues and in the liver.
    • (+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
    • Pioglitazona
    • Pioglitazone
    • Pioglitazonum
    Salts Pioglitazone Hydrochloride
    Brand names
    • Actos
    • Pioglitazone
    • Pioglitazone Hydrochloride
    Affected organism Humans and other mammals
    Indication Treatment of Type II diabetes mellitus
    Pharmacology Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent.
    Mechanism of action Pioglitazone acts as an agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPAR-gamma receptors increases the transcription of insulin-responsive genes involved in the control of glucose production, transport, and utilization. In this way, pioglitazone both enhances tissue sensitivity to insulin and reduces hepatic gluconeogenesis. Thus, insulin resistance associated with type 2 diabetes mellitus is improved without an increase in insulin secretion by pancreatic β cells.
    Route of administration
    • occlusive dressing technique
    • oral
    Categories Hypoglycemic Agents
    ATC-Code A10BG03
    AHFS-Code 68:20.28
    CAS number 111025-46-8
    Name Sequence search Pharmacological action Actions
    Peroxisome proliferator-activated receptor gamma   Search  yes agonist
Ligand Image